摘要
目的比较粒细胞集落刺激因子+阿克拉霉素+阿糖胞苷(CAG)方案与粒细胞集落刺激因子+高三尖杉酯碱+阿克拉霉素+阿糖胞苷(HAAG)方案联合地西他滨治疗老年急性髓系白血病(AML)患者的疗效及安全性。方法依据治疗方案将64例老年AML患者分为对照组与观察组,每组32例,对照组患者接受CAG方案联合地西他滨治疗,观察组患者接受HAAG方案联合地西他滨治疗。比较两组患者的临床疗效、不良反应发生情况、随访1年总生存率。结果两组患者临床疗效的比较,差异无统计学意义(P﹥0.05)。两组患者肺部感染、恶心呕吐、腹泻、肝功能受损发生率比较,差异均无统计学意义(P﹥0.05)。随访1年,观察组患者1年总生存率为46.88%,与对照组患者的53.12%比较,差异无统计学意义(P﹥0.05)。结论CAG方案与HAAG方案联合地西他滨治疗老年AML患者的疗效及安全性均无明显差异。
Objective To compare the efficacy and safety of granulocyte colony stimulating factor+aclarithromycin+cytarabine(CAG)regimen and granulocyte colony stimulating factor+homoharringtonine+aclarithromycin+cytarabine(HAAG)regimen combined with decitabine in the treatment of elderly patients with acute myelogenous leukemia(AML).Method According to the treatment program,64 elderly AML patients were divided into control group and observation group,with 32 cases in each group.The control group received CAG regimen combined with decitabine treatment,and the observation group received HAAG regimen combined with decitabine treatment.The clinical efficacy,occurrence of adverse reactions,and the 1-year overall survival rate of the two groups of patients were compared.Result There was no significant difference in clinical efficacy between the two groups of patients(P>0.05).There was no significant difference in the incidence of lung infection,nausea and vomiting,diarrhea,and liver function impairment between the two groups(P>0.05).After a 1-year follow-up,the 1-year overall survival rate of the observation group was 46.88%,which was not statistically significant compared with 53.12% of the control group(P>0.05).Conclusion There is no significant difference in the efficacy and safety of CAG regimen and HAAG regimen combined with decitabine in the treatment of elderly patients with AML.
作者
冀晓红
高蔼萍
田培军
JI Xiaohong;GAO Aiping;TIAN Peijun(Department of Hematology·Rheumatic Immunology,Shangluo Central Hospital,Shangluo 726000,Shaanxi,China;Department of Hematology,Ankang Central Hospital,Ankang 725000,Shaanxi,China)
出处
《癌症进展》
2021年第18期1910-1912,共3页
Oncology Progress
关键词
急性髓系白血病
化疗
地西他滨
acute myelogenous leukemia
chemotherapy
decitabine
